Trade WUXI BIO - 2269 CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.25
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentHK$1,000.00Overnight funding adjustmentCharges from full value of position-0.019152 %(-HK$3.83)Trade size with leverage ~ HK$20,000.00Money from leverage ~ $HK$19,000.00Go to platform: -0.01915%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentHK$1,000.00Overnight funding adjustmentCharges from full value of position-0.002766 %(-HK$0.55)Trade size with leverage ~ HK$20,000.00Money from leverage ~ $HK$19,000.00Go to platform: -0.00277%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: HKD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: Hong Kong
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: HK$1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.019152 %
  (-HK$3.83)

• Margin. Your investment: HK$1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.002766 %
  (-HK$0.55)

Key Stats

• Prev. Close: 52.85
• Open: 52.9
• 1-Year Change: 35.82%
• Day's Range: 52.4 - 53.95

Trade WUXI BIO - 2269

About WuXi Biologics (Cayman) Inc

WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing of biologics services. The Company's technology platforms include WuXiBody TM bispecific antibody technology platform and antibody drug conjugates (ADC) technology platform. It has brought in several new projects into its pipeline. The Company has a vaccine manufacturing facility and produces vaccines for customers to supply the global market. The Company conducts its businesses within the China market and to overseas markets, such as North America, Europe and other markets.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, WuXi Biologics (Cayman) Inc revenues increased 83% to RMB10.29B. Net income increased from RMB1.69B to RMB3.39B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from FV gain - unlisted investments at FVTPL increase from RMB3M to RMB74.4M (income).